A Clinical and Pharmacokinetic Study of the Effectiveness of Hepatitis C Treatment (Sofosbuvir+Daclatasvir) in HIV Co-infected and Non HIV Co-infected Patients at the Level of Non-hospital Based Management in Myanmar
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jul 2018
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 Jun 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 26 Jun 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 30 Aug 2017 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.